Feasibility of disease terminology systems for mapping orphan conditions and therapeutic indications of designated orphan medicines in the European Union
Regulatory data concerning orphan conditions and therapeutic indications of designated orphan medicines seem to be best covered by SNOMED CT. However, which disease terminology system best facilitates systematic evaluation and communication about development and authorisation of designated orphan medicines also depends on the specific use case. Given the frequent use of SNOMED CT in healthcare settings, it may also facilitate interoperability between regulatory and healthcare data, while for example ICD-11 may be better suited to generate statistics concerning drug development for rare diseases.
Authors
- Violeta Stoyanova‐Beninska (ORCID: https://orcid.org/0000-0002-7521-165X)
- Anna M.G. Pasmooij (ORCID: https://orcid.org/0000-0003-0641-3829)
- Hubert G. M. Leufkens (ORCID: https://orcid.org/0000-0002-7175-1499)
- Lourens T. Bloem (ORCID: https://orcid.org/0000-0002-0014-8625)
- Keerti D Jadoenathmisier
- Inge M Soons
Institutions
- Utrecht University (NL)
- Pharmo Institute (NL)
- Nationaal ICT Instituut in de Zorg (NL)
- Medicines Evaluation Board (NL)
Publication Details
- Journal
- European Journal of Pharmaceutical Sciences
- Published
- 2024-08-05
- DOI
- https://doi.org/10.1016/j.ejps.2024.106871
- Citations
- 1
- Primary Topic
- Genomics and Rare Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.55